Accuray Incorporated (ARAY)
NASDAQ: ARAY · Real-Time Price · USD
2.110
-0.050 (-2.31%)
Feb 21, 2025, 4:00 PM EST - Market closed
Accuray Revenue
Accuray had revenue of $116.17M in the quarter ending December 31, 2024, with 8.33% growth. This brings the company's revenue in the last twelve months to $453.14M, up 1.26% year-over-year. In the fiscal year ending June 30, 2024, Accuray had annual revenue of $446.55M, down -0.24%.
Revenue (ttm)
$453.14M
Revenue Growth
+1.26%
P/S Ratio
0.47
Revenue / Employee
$459,108
Employees
987
Market Cap
216.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 446.55M | -1.05M | -0.24% |
| Jun 30, 2023 | 447.61M | 17.70M | 4.12% |
| Jun 30, 2022 | 429.91M | 33.62M | 8.48% |
| Jun 30, 2021 | 396.29M | 13.36M | 3.49% |
| Jun 30, 2020 | 382.93M | -35.86M | -8.56% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ARAY News
- 16 days ago - Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance - PRNewsWire
- 4 weeks ago - Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product - PRNewsWire
- 4 weeks ago - Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025 - PRNewsWire
- 4 weeks ago - Leonel Peralta to Join Accuray as Chief Operations Officer - PRNewsWire
- 5 weeks ago - Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System - PRNewsWire
- 6 weeks ago - Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If' - Seeking Alpha
- 2 months ago - New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat - PRNewsWire